Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-02T23:16:05.650Z Has data issue: false hasContentIssue false
  • English
  • Français

Tegretol (Carbamazepine): A Controlled Trial of a New Anti-Convulsant

Published online by Cambridge University Press:  29 January 2018

C. A. K. Bird ,
B. P. Griffin ,
J. M. Miklaszewska  and
A. W. Galbraith
C. A. K. Bird
Affiliation:
Macclesfield and District Hospitals
B. P. Griffin
Affiliation:
Cranage Hall Hospital, Holmes Chapel, Cheshire
J. M. Miklaszewska
Affiliation:
Cranage Hall Hospital, Holmes Chapel, Cheshire
A. W. Galbraith
Affiliation:
Geigy Pharmaceutical Company
Get access Rights & Permissions [Opens in a new window]

Extract

Tegretol (carbamazepine; 5-carbamyl-5H-dibenz (b, f) azepine) has been under investigation since 1958 in the treatment of epilepsy on the continent of Europe, following the demonstration of its anticonvulsant properties in animals by Theobald and Kunz (1963). Clinical reports have been enthusiastic (Lorgé, 1963, Bonduelle et al., 1963). The present investigation was undertaken with a view to a more critical appraisal of this drug, avoiding the dangers of sudden alteration of anticonvulsant therapy in epileptic patients, documented by Schwab et al. (1959), while still maintaining the double-blind nature of the trial.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 112 , Issue 488 , July 1966 , pp. 737 - 742
Copyright
Copyright © Royal College of Psychiatrists, 1966 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bonduelle, M. et al. (1963). “Tegretol (Geigy)–G.32883. 5-carbamyl 5H- dibenzo (b, f,) azepine”. Thérapie, 18, 543.Google Scholar
Handley, R. and Stewart, A. S. R. (1952). “Mysoline: a new drug in the treatment of epilepsy”. Lancet, 1, 742.CrossRefGoogle Scholar
Lorgé, M. (1963). “Klinische Erfahrungen mit einem neuen Antiepilepticum, Tegretol (G.32883) mit besonderer Wirkung auf die epileptische Wesensveränderung,” Schweiz. med. Wschr., 93, 1042.Google Scholar
Pakesch, E. (1963). “Untersuchungen über ein neuartiges Antiepileptikum”. Wien. med. Wschr., 113, 794.Google Scholar
Schwab, R. S. et al. (1959). “Problems in the clinical evaluation in the use of anticonvulsants”. Epilepsia, (Amst.), 1, 575.CrossRefGoogle Scholar
Spillane, J. D. (1964). “The treatment of trigeminal neuralgia. Preliminary experiences with Tegretol”. Practitioner, 192, 71.Google Scholar
Theobald, W. and Kunz, H. A. (1963). “Zur Pharmacologic des Antiepilepticums 5-Carbamyl-5H- dibenzo (b, f) azepin”. Arzneimittel-Forsch., 13, 122.Google Scholar
Wilson, J. et al. (1959). “Beclamide in intractable epilepsy: a controlled trial”. Brit. med. J., 1, 1275.CrossRefGoogle Scholar
Submit a response

eLetters

No eLetters have been published for this article.